Thank you for reading my research on Seeking Alpha. If you want to learn even more about my method and how I discover these investment opportunities, please check out my subscription marketplace service, Compounding Healthcare , and sign up for a free trial.It has been roughly five months since my previous Regeneron Pharmaceuticals (NASDAQ: REGN ) article , where I discussed how Regeneron was still a “biotech juggernaut” thanks to their key brands of Dupixent, EYLEA, and Libtayo performing well, while other ...